ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2421

Whole Blood Immune Phenotyping Reveals Cytometric Differences in B Cell Clusters Between Lupus Nephritis and Non-Lupus Nephritis SLE Patients with Minimal Proteinuria

Nicholas Bauer1, Philip Carlucci2, Rufei Lu1, Carla Guthridge1, Tayte Stephens3, Benjamin Jones4, Wade DeJager5, Susan Macwana1, Andrea Fava6, Sanchit Sanyal7, Erin Carter8, Mala Masson9, Jennifer Anolik10, Jennifer Barnas11, Peter Izmirly12, H Michael Belmont13, Kelly Ruggles14, Study Team ALE06 Clinical1, Brad Rovin15, Jill Buyon16, Michelle Petri17, Judith James1 and Joel Guthridge1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2New York University School of Medicine, New York, NY, 3University of Oklahoma Health Science Center, Oklahoma City, OK, 4Oklahoma State University, Oklahoma City, OK, 5Oklahoma Medical Research Foundation, Oklahoma City, 6Johns Hopkins University, Baltimore, MD, 7Johns Hopkins University School of Medicine, Baltimore, MD, 8New York University Grossman School of Medicine, New York, NY, 9NYU Langone Medical Center- Division of Rheumatology, New York, NY, 10University of Rochester Medical Center, Rochester, NY, 11University of Rochester, Rochester, NY, 12New York University Grossman School of Medicine, New York, NY, 13NYU School of Medicine, New York, NY, 14NYU Grossman School of Medicine, Brooklyn, NY, 15The Ohio State University, Columbus, OH, 16NYU Grossman School of Medicine, New York, NY, 17Johns Hopkins University School of Medicine, Timonium, MD

Meeting: ACR Convergence 2025

Keywords: autoimmune diseases, B-Lymphocyte, immunology, Lupus nephritis, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2377–2436) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Autoreactive B cell populations play a key role in the pathogenesis of lupus nephritis (LN). Therefore, it is hypothesized that dysregulation in the B cell compartment may be an early indicator of kidney involvement in SLE. The AMP-AIM lupus nephritis study was initiated to identify molecular drivers of kidney disease in SLE patients with minimal proteinuria (considered “early” disease). Accordingly, this study leveraged CyTOF performed at the time of a kidney biopsy in AMP-AIM to characterize alterations within the B cell lineage between LN and non-LN cases and within LN disease classes.

Methods: Twenty-five patients fulfilling diagnostic criteria for SLE with a urine protein creatinine ratio between 0.25 – 0.49 without a history of LN but an additional risk factor for LN including active sediment and/or serologies were enrolled in AMP-AIM. Whole blood was collected at the time of their kidney biopsy and stained at the point of collection on the same day using the Maxpar Direct Immune Profiling Assay (MDIPA), a comprehensive panel of 30 markers to capture the broad immune phenotype of the samples. The samples were stabilized and shipped to a central location where data were captured using the CyTOF XT platform. Low-quality events were excluded with FlowCut and cells were gated to include only the B cell lineage. Dimension reduction and clustering were performed using ClusterX. All pairwise comparisons were made with the Wilcoxon rank-sum test.

Results: Table 1 shows the clinical characteristics of the patients with and without LN at biopsy. ClusterX captured a total of 15 clusters within B cells (Figure 1A & 1B). Two clusters, both CD11c positive, were elevated in LN vs non-LN cases (Figure 2). One was IgD positive (B12) and the other was IgD negative (B6) (p=0.023 and p=0.0024 respectively). A naïve B cell cluster characterized as CXCR3 positive and CXCR5 positive (B9) was also expanded in LN compared to non-LN cases (p=0.0048). Surprisingly, elevated frequencies for all three clusters were seen in class V compared to class III (B6, p=0.18; B9, p=0.052; B12, p=0.082) (Figure 2). An additional CXCR5 and CCR7 positive naïve B cell cluster (B5) was also significantly elevated in class V compared to class III (p=0.034). These differences were also reflected in hierarchical clustering of the samples (Figure 2B).

Conclusion: Whole blood profiling at the point of collection, which likely reduced artifactual findings compared to prior studies which have relied on PBMCs, yielded several differences between LN and non-LN cases at the time of biopsy. These data suggest B cell dysregulation may be detected “early” in kidney involvement in SLE patients, especially with class V histology. Whole blood profiling at the point of collection, which likely reduced artifactual findings compared to prior studies which have relied on PBMCs, yielded several differences between LN and non-LN cases at the time of biopsy. These data suggest B cell dysregulation may be detected “early” in kidney involvement in SLE patients, especially with class V histology.

Supporting image 1Table 1: Clinical characteristics of patients with and without LN. Data are represented as median [IQR], or n (%). *4 non LN but unknown other histology, 2 arteriosclerosis, 1 diabetic nephropathy, 1 microangiopathy.

Supporting image 2Figure 1. B cell clusters in LN and Non LN cases. (A): Uniform Manifold Approximation and Projection (UMAP) dimension reduction visualizing the different B cell clusters (top left) and the differences in their density (top right) (B): Marker expression in each of the B cell clusters (C): PCA based on B cell clusters colored by biopsy histology.

Supporting image 3Figure 2. Four B cell clusters differentiate LN and non LN (A): Boxplots showing the four B cell clusters significantly different between Non LN and LN cases. LN is further divided into mesangial, membranous, and proliferative histology. P-values for Non LN vs LN and membranous vs proliferative are reported (B): Heatmap showing the expression of each cluster in all cases.


Disclosures: N. Bauer: None; P. Carlucci: None; R. Lu: None; C. Guthridge: None; T. Stephens: None; B. Jones: None; W. DeJager: None; S. Macwana: None; A. Fava: Artiva, 2, AstraZeneca, 1, 2, Bain Capital, 2, Biogen, 1, Bristol-Myers Squibb(BMS), 2, Exagen, 5, 9, Quotient Therapeutics, 2, UCB, 6, Zenas, 2; S. Sanyal: None; E. Carter: None; M. Masson: None; J. Anolik: None; J. Barnas: None; P. Izmirly: Hansoh Bio, 2; H. Belmont: None; K. Ruggles: None; S. ALE06 Clinical: None; B. Rovin: Alexion, 2, Artiva, 2, 11, AstraZeneca, 2, Aurinia, 2, 5, Biogen, 2, 5, Bristol Myers Squibb, 2, Cabelleta, 2, Century, 2, F. Hoffman-La Roche Ltd/Genentech, Inc., 2, GlaxoSmithKlein(GSK), 2, Novartis, 2; J. Buyon: Artiva Biotherapeutics, 2, Biogen, 2, Bristol-Myers Squibb(BMS), 2, Celgene, 2, CLIMB Bio Operating, 2, GlaxoSmithKlein(GSK), 2, Janssen, 2, Related Sciences, 2, UCB, 2; M. Petri: Amgen, 2, AnaptysBio, 2, Annexon Bio, 2, AstraZeneca, 2, 5, Atara Biosciences, 2, Aurinia, 2, 5, Autolus, 2, Bain Capital, 2, Baobab Therapeutics, 2, Biocryst, 2, Biogen, 2, Boxer Capital, 2, Cabaletto Bio, 2, Caribou Biosciences, 2, CTI Clinical Trial and Consulting Services, 2, CVS Health, 2, Dualitybio, 2, Eli Lilly, 2, 5, EMD Serono, 2, Emergent, 2, Escient Pharmaceuticals, 2, Exagen, 5, Exo Therapeutics, 2, Gentibio, 2, GlaxoSmithKlein(GSK), 2, 5, iCell Gene Therapeutics, 2, Innovaderm Research, 2, IQVIA, 2, Janssen, 5, Kezar Life Sciences, 2, Kira Pharmaceuticals, 2, Nexstone Immunology, 2, Nimbus Lakshmi, 2, Novartis, 2, Ono Pharma, 2, PPD Development, 2, Proviant, 2, Regeneron, 2, Seismic Therapeutic, 2, Senti Biosciences, 2, Sinomab Biosciences, 2, Steritas, 2, Takeda, 2, Tenet Medicines, 2, TG Therapeutics, 2, UCB, 2, Variant Bio, 2, Worldwide Clinical Trials, 2, Zydus, 2; J. James: GlaxoSmithKlein(GSK), 2, Progentec, 5; J. Guthridge: None.

To cite this abstract in AMA style:

Bauer N, Carlucci P, Lu R, Guthridge C, Stephens T, Jones B, DeJager W, Macwana S, Fava A, Sanyal S, Carter E, Masson M, Anolik J, Barnas J, Izmirly P, Belmont H, Ruggles K, ALE06 Clinical S, Rovin B, Buyon J, Petri M, James J, Guthridge J. Whole Blood Immune Phenotyping Reveals Cytometric Differences in B Cell Clusters Between Lupus Nephritis and Non-Lupus Nephritis SLE Patients with Minimal Proteinuria [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/whole-blood-immune-phenotyping-reveals-cytometric-differences-in-b-cell-clusters-between-lupus-nephritis-and-non-lupus-nephritis-sle-patients-with-minimal-proteinuria/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/whole-blood-immune-phenotyping-reveals-cytometric-differences-in-b-cell-clusters-between-lupus-nephritis-and-non-lupus-nephritis-sle-patients-with-minimal-proteinuria/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology